One in 5 patients treated with adjuvant pembrolizumab experienced serious adverse events, so it remains important to weigh the risk vs benefits of the therapy for each individual patient. Overall survival data support adjuvant pembrolizumab after surgery as standard of care for select patients with clear cell renal cell carcinoma.
Overall survival data support adjuvant pembrolizumab after surgery as standard care for select patients with clear cell renal cell carcinoma, according to researchers. Overall survival data support adjuvant pembrolizumab after surgery as standard care for select patients with clear cell renal cell carcinoma.
One in 5 patients treated with adjuvant pembrolizumab experienced serious adverse events, so it remains important to weigh the risk vs benefits of the therapy for each individual patient. Overall survival data support adjuvant pembrolizumab after surgery as standard of care for select patients with clear cell renal cell carcinoma.
Opdivo failed to improve disease-free survival in patients with localized renal cell carcinoma at high risk of relapse, according to findings from CheckMate 914.